JPMorgan Chase & Co. Increases Henry Schein (NASDAQ:HSIC) Price Target to $92.00

Henry Schein (NASDAQ:HSIC) had its price target raised by analysts at JPMorgan Chase & Co. from $78.00 to $92.00 in a report released on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 12.35% from the company’s current price.

A number of other research firms also recently issued reports on HSIC. Barclays assumed coverage on shares of Henry Schein in a report on Monday, December 8th. They set an “overweight” rating and a $86.00 price objective for the company. Wells Fargo & Company increased their target price on shares of Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research report on Wednesday. Barrington Research set a $79.00 price target on shares of Henry Schein and gave the stock an “outperform” rating in a report on Wednesday, November 5th. Morgan Stanley upped their price objective on Henry Schein from $58.00 to $61.00 and gave the company an “underweight” rating in a research note on Wednesday. Finally, Robert W. Baird set a $100.00 price objective on Henry Schein and gave the company an “outperform” rating in a report on Monday. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $82.67.

Henry Schein Stock Performance

Henry Schein stock traded down $1.46 during mid-day trading on Wednesday, reaching $81.89. 1,082,759 shares of the company’s stock were exchanged, compared to its average volume of 1,384,953. The business’s fifty day simple moving average is $77.56 and its 200 day simple moving average is $71.90. The company has a quick ratio of 0.79, a current ratio of 1.40 and a debt-to-equity ratio of 0.54. Henry Schein has a one year low of $60.56 and a one year high of $89.29. The firm has a market capitalization of $9.64 billion, a PE ratio of 25.90, a P/E/G ratio of 2.40 and a beta of 0.88.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.04. The firm had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.34 billion. Henry Schein had a return on equity of 14.76% and a net margin of 3.02%.The business’s revenue was up 7.7% compared to the same quarter last year. During the same period last year, the firm posted $1.19 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, sell-side analysts expect that Henry Schein will post 4.74 earnings per share for the current year.

Institutional Trading of Henry Schein

A number of hedge funds and other institutional investors have recently made changes to their positions in HSIC. CYBER HORNET ETFs LLC bought a new position in Henry Schein in the 2nd quarter worth about $25,000. MUFG Securities EMEA plc purchased a new stake in shares of Henry Schein in the second quarter worth about $27,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Henry Schein in the fourth quarter worth about $30,000. Federated Hermes Inc. bought a new position in shares of Henry Schein in the fourth quarter valued at approximately $32,000. Finally, Los Angeles Capital Management LLC purchased a new position in Henry Schein during the fourth quarter valued at approximately $37,000. 96.62% of the stock is currently owned by institutional investors.

Trending Headlines about Henry Schein

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Q4 results beat expectations — EPS $1.34 vs. $1.30 est., revenue $3.44B vs. $3.34B; revenue grew ~7.7% year/year, driven by dental and medical equipment strength. Reuters: Henry Schein beats quarterly profit estimates
• Positive Sentiment: FY2026 guidance roughly in line or slightly above Street: EPS guide 5.230–5.370 (consensus ~5.280) and revenue guide $13.6B–$13.8B (above ~$13.5B consensus) — supports continued revenue growth expectations. Press Release / Slide Deck
• Positive Sentiment: Multiple analyst upgrades/price-target raises after results: Robert W. Baird upgraded to Outperform with a $100 PT; Wells Fargo and Leerink raised targets to $87. These increases signal incremental analyst confidence in the recovery story. Benzinga / The Fly
• Neutral Sentiment: Market reaction earlier pushed shares to a 52-week high as investors digested the beat and guidance. Coverage and call transcripts are available for detailed read-through of management’s commentary. Benzinga: 52-week high
• Neutral Sentiment: Earnings call and transcripts note strategic wins and product strength but are mixed on timing of margin recovery — useful for longer-term thesis but not an immediate catalyst. Seeking Alpha: Q4 earnings call transcript
• Negative Sentiment: Margin pressure highlighted by analysts and some coverage: gross/margin contraction in the quarter tempers the upside from sales growth and is cited as a reason for cautious ratings. Zacks: Margins down
• Negative Sentiment: Bearish analyst stance persists: Morgan Stanley/Morgan analyst maintained a Sell/Underweight view with a ~$58–61 PT (well below current levels), keeping downside risk if margins or execution disappoint. TipRanks: Sell rating maintained

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.